Equillium Inc (EQ)
NASDAQ:EQ
Want to see EQ full AI Analyst Report?
EQ Stock Chart & Stats
$2.05
-$0.05(-6.85%)
At close: 4:00 PM EST
$2.05
-$0.05(-6.85%)
Day’s Range― - ―
52-Week Range$0.27 - $3.12
Previous CloseN/A
Volume484.47K
Average Volume (3M)883.61K
Market Cap
$176.40M
Enterprise Value$42.38M
Total Cash (Recent Filing)$61.32M
Total Debt (Recent Filing)$692.00K
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Aug 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding63,226,555
10 Day Avg. Volume862,141
30 Day Avg. Volume883,611
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-6.25
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-536.48
Enterprise Value/Ebitda-2.09
Forecast
1Y Price Target
$7.57Price Target Upside269.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityExtremely low debt substantially reduces solvency risk for a pre-revenue biotech. With minimal interest burden the company has structural flexibility to prioritize R&D spending, negotiate partner deals, or raise equity under less strain than highly leveraged peers, improving strategic optionality.
Committed $35M Financing Extends RunwayAn institutional private placement from a healthcare specialist materially bolsters near-term funding for clinical development of EQ504. This committed capital reduces immediate refinancing pressure and supports program milestones, lowering execution risk over the next several quarters while the company advances trials.
Focused Immunomodulatory PipelineA clear R&D focus on immune signaling and targeted biologics concentrates technical expertise and allows resource prioritization. If clinical data validate mechanisms, the company can leverage high unmet need in severe autoimmune disorders to attract partners or premium pricing, a durable strategic advantage.
Bears Say
Near-zero Recurring RevenueThe abrupt loss of meaningful revenue signals the company no longer has reliable commercial or partner inflows. Sustained absence of operating revenue forces reliance on financing rather than operating cash generation, increasing long-term execution and valuation risk absent successful trial readouts or new partnerships.
Heavy Cash Burn And Negative Cash FlowPersistent negative operating and free cash flow erodes liquidity and makes the business dependent on external capital. Continued burn at current rates means timelines to pivotal data could outlast available runway, necessitating dilutive raises that can constrain upside for long-term investors.
Expanded Share Authorization & Reverse-split PowersBoard-approved tools to adjust capital structure (reverse split, doubled authorized shares) materially increase the company's ability to issue equity or restructure share count. While useful for financing, they raise the risk of dilution and indicate reliance on future equity transactions to fund operations.
Equillium News
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.27 and its highest was $3.12 in the past 12 months.
What is Equillium Inc’s market cap?
Equillium Inc’s market cap is $176.40M.
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on May 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.014.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -0.05.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 63,226,555 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 12.121%.
Which hedge fund is a major shareholder of Equillium Inc?
Currently, no hedge funds are holding shares in EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Equillium Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.57 (269.34% Upside)
$7.57 (269.34% Upside)
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 45.6%
Last 30 Days ▲ 54.3%
Last 30 Days ▲ 54.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.18%
12-Months-Change
Fundamentals
Return on Equity
-61.43%
Trailing 12-Months
Asset Growth
277.09%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
EQ Stock 12 Month Forecast
Average Price Target
$7.57
▲(269.34% Upside)
Technical Analysis
Ownership Overview
13.41% Insiders
3.29% Mutual Funds
38.11% Other Institutional Investors
42.40% Public Companies and
Individual Investors